ArticleFrontiers in surgery2022
Prediction for 2-year mortality of metastatic ovarian cancer patients based on surveillance, epidemiology, and end results database.
Article in Frontiers in surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Survival Difference in Advanced-Stage Cervical and Ovarian Cancer Patients Treated with Concomitant Modulated Electro-Hyperthermia in Comparison to Classic Treatment Modalities: Results of a Pilot Study and Meta-Analysis.Medical sciences (Basel, Switzerland) · 2026Pooled it
- LINE-1 Deregulation in Ovarian Cancer: Implications for Diagnosis, Prognosis, and Therapeutic Targeting.Molecular diagnosis & therapy · 2026Review
- Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients.International journal of cancer · 2026Article
- Impact of single-site distant metastases on prognosis in advanced ovarian cancer: a Surveillance, Epidemiology, and End Results population-based study.Translational cancer research · 2025Article
- The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer.The oncologist · 2024Article
- Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial.Translational oncology · 2024Article
- Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER.PloS one · 2024Article
- Dysregulation of Cholesterol Homeostasis in Ovarian Cancer.Current oncology (Toronto, Ont.) · 2023Review
- Single-cell RNA sequencing reveals a pro-metastatic subpopulation and the driver transcription factor NFE2L1 in ovarian cancer cells.Genes & genomics · 2023Article
- Suppression of Metastatic Ovarian Cancer Cells by Bepridil, a Calcium Channel Blocker.Life (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To establish prediction models for 2-year overall survival of ovarian cancer patients with metastasis. Methods: In total, 4,929 participants from Surveillance, Epidemiology, and End Results (SEER) database were randomly divided into the training set ( Results: At the end of follow-up, 2,587 patients were survived and 2,342 patients were dead within 2 years. The 2-year survival rate was 52.5%. The prediction models were constructed based on predictors including age, radiation, surgery and chemotherapy, CA125, and bone, liver, and lung metastasis. The prediction model for 2-year overall survival of ovarian cancer patients with metastasis showed good predictive ability with the C-index of the model of 0.719 (95% CI: 0.706-0.731) in the training set and 0.718 (95% CI: 0.698-0.737) in the testing set. In terms of patients with bone metastasis, the C-index was 0.740 (95% CI: 0.652-0.828) for predicting the 2-year overall survival of ovarian cancer patients. The C-index was 0.836 (95% CI: 0.694-0.979) in patients with brain metastasis, 0.755 (95% CI: 0.721-0.788) in patients with liver metastasis and 0.725 (95% CI: 0.686-0.764) in those with lung metastasis for predicting the 2-year overall survival of ovarian cancer patients. Conclusion: The models showed good predictive performance for 2-year overall survival of metastatic ovarian cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.